Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Feb 24
8-K
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
26 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
22 Aug 23
DEFA14A
Additional proxy soliciting materials
16 Aug 23
DEFA14A
Additional proxy soliciting materials
15 Aug 23
8-K
Moringa Acquisition Corp Announces Contribution to Trust Account In Connection with Proposed Extension
15 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
DEFA14A
Additional proxy soliciting materials
10 Aug 23
8-K
Termination of a Material Definitive Agreement
10 Aug 23
DEF 14A
Definitive proxy
26 Jul 23
UPLOAD
Letter from SEC
26 Jul 23
PRER14A
Preliminary revised proxy
25 Jul 23
PRER14A
Preliminary revised proxy
24 Jul 23
CORRESP
Correspondence with SEC
24 Jul 23
UPLOAD
Letter from SEC
20 Jul 23
PRE 14A
Preliminary proxy
13 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Mar 23
8-K
Entry into a Material Definitive Agreement
9 Feb 23
DEFA14A
Additional proxy soliciting materials
7 Feb 23
8-K
Moringa Acquisition Corp Announces Adjournment of Extraordinary
7 Feb 23
DEFA14A
Additional proxy soliciting materials
26 Jan 23
8-K
Moringa Acquisition Corp Announces Contribution to Trust Account In Connection with Proposed Extension
26 Jan 23
DEF 14A
Definitive proxy
5 Jan 23
425
Business combination disclosure
4 Jan 23
8-K
Entry into a Material Definitive Agreement
4 Jan 23
UPLOAD
Letter from SEC
23 Dec 22
CORRESP
Correspondence with SEC
22 Dec 22
UPLOAD
Letter from SEC
20 Dec 22
PRE 14A
Preliminary proxy
15 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
425
Business combination disclosure
6 Sep 22
8-K
Termination of a Material Definitive Agreement
6 Sep 22
425
Business combination disclosure
17 Aug 22
8-K
Entry into a Material Definitive Agreement
17 Aug 22
Latest ownership filings
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
SC 13G/A
ARISTEIA CAPITAL, L.L.C.
12 Feb 24
SC 13G/A
Saba Capital Management, L.P.
8 Feb 24
SC 13G
Yakira Capital Management, Inc.
26 Jan 24
SC 13G/A
GLAZER CAPITAL, LLC
11 Sep 23
4
Change in insider ownership
24 Aug 23
3
Sander Gerber
5 Apr 23
SC 13G/A
GLAZER CAPITAL, LLC
10 Mar 23
SC 13G
Radcliffe Capital Management, L.P.
16 Feb 23
SC 13G
GLAZER CAPITAL, LLC
14 Feb 23
SC 13G/A
Saba Capital Management, L.P.
14 Feb 23
SC 13G
ARISTEIA CAPITAL LLC
13 Feb 23
SC 13G
Moringa Sponsor US L.P.
15 Feb 22
SC 13G/A
Saba Capital Management, L.P.
14 Feb 22
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 22
SC 13G/A
Linden Capital L.P.
4 Feb 22
3
Dan Yalon
18 Mar 21
SC 13G
Saba Capital Management, L.P.
12 Mar 21
4
Ilan Levin
4 Mar 21
3
Initial statement of insider ownership
4 Mar 21
3
Gil Maman
4 Mar 21
3
Ilan Levin
4 Mar 21
SC 13G
Radcliffe Capital Management, L.P.
4 Mar 21
3
Ruth Alon
2 Mar 21
3
Eric Brachfeld
2 Mar 21
3
Michael Basch
2 Mar 21
SC 13G
Linden Capital L.P.
1 Mar 21